CDK (cyclin-dependent kinase) inhibitor

Abemaciclib - Palbociclib - Ribociclib      

pathologytreatmentpatient Demonstrated benefit and harm k      
advanced breast cancer (metastatic)abemaciclib not classified

versus endocrine therapy alone

Abemaciclib +nsAI superior to nsAI in terms of progression free survival in MONARCH 3, 2017

1 trialmeta-analysis
advanced breast cancer (metastatic)palbociclib not classified

versus endocrine therapy alone

No demonstrated result for efficacy

1 trialmeta-analysis
advanced breast cancer (metastatic)palbociclib 2nd line

versus endocrine therapy alone

palbociclib + fulvestrant superior to fulvestrant alone in terms of progression free survival in PALOMA 3, 2015 (2nd line patients)

1 trialmeta-analysis
advanced breast cancer (metastatic)palbociclib first line

versus endocrine therapy alone

palbociclib + letrozole superior to letrozole alone in terms of progression free survival in PALOMA-2, 2016 (first line patients)

1 trialmeta-analysis
advanced breast cancer (metastatic)ribociclib first line

versus endocrine therapy alone

ribociclib (LEE011) + letrozole superior to letrozole alone in terms of progression free survival in MONALEESA-2, 2016 (first line patients)

1 trialmeta-analysis
lung cancer (metastatic)abemaciclib 2nd line

versus

No demonstrated result for efficacy

1 trialmeta-analysis